1 AIM penny stock I’d buy and hold till the 2030s!

This volatile AIM-listed penny stock remains well down from its all-time high. I’d buy shares at 27p today and hold them into the next decade.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Female Doctor In White Coat Having Meeting With Woman Patient In Office

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Investing in penny stocks isn’t for the risk-averse. They’re often sensitive to any piece of market news and there’s low liquidity. This means they can be extremely volatile, with sudden movements one way or the other. On the other hand, finding the right penny stock can be a very rewarding activity.

Here’s why I think this small-capitalised company has enriching potential at 27p.

Volatile stock

Creo Medical (LSE: CREO) shares epitomise volatility. After going public at 77p in 2016, the stock proceeded to double within two years. Then it went up and down for three years, before plunging all the way down to 18p. Now the shares are at 27p, having rocketed 42% in the past month.

The stock lost over 80% of its value in 2022. The reason was fear about the company’s dwindling cash reserves. However, last month the firm announced that an oversubscribed fundraise had brought in £28.5m. And there’s the potential for an extra £5.2m from an open offer of stock.

Craig Gulliford, CEO of Creo, said: “This funding round will not only provide us with the working capital to accelerate the roll out of our core technology, but will also resolve the funding gap to provide us with a pathway to being cash flow breakeven and, ultimately, to profitability.”

This fresh injection of capital into the business has now removed liquidity concerns. Investors can instead focus on the market opportunity ahead, which I believe is substantial.

Cutting-edge technology

The company has developed a suite of minimally-invasive electrosurgical devices. All six of its products have been CE marked and five are also cleared for use in the US.

Its flagship product is called Speedboat. This device can be attached to an endoscope to cut out or vaporise pre-cancerous growths in the digestive tract before they spread. Endoscopes are normally used to investigate rather than perform treatments, so this innovation benefits patients and ultimately saves healthcare systems money.

Creo’s devices are powered by an advanced energy platform called CROMA. Importantly, the firm has started to licence this patented technology to other companies, including global robotics giant Intuitive Surgical. The company has already received its first income from this non-exclusive licensing deal (around £1.4m), and expects additional milestone payments, as well as growing device sales revenue.

These intellectual property deals with Intuitive is a huge endorsement of Creo’s technology, and the company expects to announce more such licensing deals in the future.

The stock

Analysts expect the firm to post £27m in sales for fiscal 2022. That’s from basically nothing in fiscal 2019, when its devices first started generating revenue. But the company is still loss-making, and the risk is that it remains so. At the very least, it will have to significantly increase sales next year to justify its current £56m market cap.

However, the stock’s price-to-sales (P/S) ratio of two doesn’t look too demanding. And with cash no longer an issue, most analysts believe the company has a clear path towards being cash generative in 2025.

Overall, I think the stock has immense long-term potential. That’s why I recently topped up my holding.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Ben McPoland has positions in Creo Medical and Intuitive Surgical. The Motley Fool UK has recommended Intuitive Surgical. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young black man looking at phone while on the London Overground
Investing Articles

1 delicious penny stock I reckon can deliver juicy returns and growth

This food delivery penny stock has experienced a surge in performance and uptake recently. Our writer is excited by its…

Read more »

Investing Articles

If I’d bought Rolls-Royce shares the day Tufan Erginbilgiç joined here’s what I’d have now

Harvey Jones is startled by just how fast the Rolls-Royce share price has risen since its transformative CEO took over.…

Read more »

Mature Caucasian woman sat at a table with coffee and laptop while making notes on paper
Investing Articles

How much do I need to invest in Lloyds shares to earn income of £1,000 a year?

Harvey Jones is getting income and growth from his Lloyds shares but wished he'd bought more of them. So he's…

Read more »

Illustration of flames over a black background
Investing Articles

Down 75%! Will the Saga share price ever be loved again?

The last few years have been incredibly difficult for those watching the Saga share price. But what does the future…

Read more »

Investing Articles

What kind of return could I expect by investing £100 monthly in a Stocks and Shares ISA?

Using a Stocks and Shares ISA to avoid capital gains tax could grow a £100 monthly investment into a second…

Read more »

Young woman working at modern office. Technical price graph and indicator, red and green candlestick chart and stock trading computer screen background.
Investing Articles

Can strong operational momentum keep the Informa share price rising?

FTSE 100 company Informa has been performing well, but this may be just the beginning of a multi-year trend for…

Read more »

Market Movers

What’s going on with the Britvic share price?

Jon Smith flags up why Britvic's share price is surging on Friday, but believes that the company is in a…

Read more »

Cheerful young businesspeople with laptop working in office
Dividend Shares

2 super-cheap passive income shares I’m eyeing up right now

Jon Smith discusses two of his favourite passive income shares in the banking and property sectors, both featuring yields above…

Read more »